Cardiovascular & Hematological Disorders-Drug Targets
Title:Acknowledgements to Reviewers
Volume: 14 Issue: 3
Export Options
About this article
Cite this article as:
Acknowledgements to Reviewers, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X1403141002115112
DOI https://dx.doi.org/10.2174/1871529X1403141002115112 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
19
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPAR Ligands Containing Stilbene Scaffold
Mini-Reviews in Medicinal Chemistry Recent Advancements in Identification of Novel Drug Targets and Drug Delivery for Cardiovascular and Hematological Disorders
Cardiovascular & Hematological Disorders-Drug Targets The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease
Current Molecular Medicine Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men
Current Pharmaceutical Design ADIE - Nursing Interventions of Diabetic Foot Ulcer: An Integrative Review of the Literature
Current Diabetes Reviews Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome
Current Vascular Pharmacology Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension
Current Pharmaceutical Biotechnology Degradation Kinetic and Pharmacokinetic Studies of Quercetin Chitosan Nanoparticles Using Validated Ultra High Performance Liquid Chromatography- Synapt Mass Spectrometry (UPLC-MS/MS-ESI-Q-TOF)
Current Pharmaceutical Analysis What is the Real Efficacy of Beta-Blockers for the Treatment of Essential Hypertension?
Current Pharmaceutical Design Patient, Disease, and Drug-Related Risk Factors Associated with Phenytoin- Induced Cutaneous Adverse Drug Reactions in South Indian Epileptic Patients - A Prospective Case-Control Study
Current Drug Safety Meet Our Editorial Board Member
Current Neuropharmacology Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action
Current Medicinal Chemistry Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Computational Biological Analysis Reveals a Role for Nitric Oxide Synthase and Adiponectin in the Pathobiology of Insulin Resistance Syndrome and Coronary Artery Disease
Current Nutrition & Food Science The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Recent Patents on Cardiovascular Drug Discovery Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Editorial(Thematic Issue: Hypertension and Diabetes – Update in 2013)
Current Hypertension Reviews Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets